Roche Holding AG
Suletud
SektorTervishoid
325.6 0.74
Ülevaade
Aktsiahinna muutus
24h
Min
325.4
Max
326.6
Sissetulek | 1.8B 5.5B |
|---|---|
Müük | 15B 31B |
P/E Sektori keskmine | 20.461 67.147 |
Dividenditootlus | 2.97 |
Kasumimarginaal | 17.892 |
Töötajad | 103,249 |
EBITDA | 5.1B 12B |
Dividenditootlus Sektori keskmine | 2.97% 2.36% |
|---|
Turukapital | -28B 261B |
|---|---|
Eelmine avamishind | 324.86 |
Eelmine sulgemishind | 325.6 |
Uudiste sentiment
By Acuity
14%
86%
24 / 347 Pingereas Healthcare
Roche Holding AG Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Roche Holding AG Prognoos
Sentiment
By Acuity
24 / 347 Pingereas Tervishoid
Uudiste sentiment
Väga tugevad tõusu märgid
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Üle keskmise
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.
